Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Синдром Стивенса-Джонсона и синдром Лайелла у взрослых

Список литературы

  1. Seminario-Vidal L., Kroshinsky D., Malachowski S.J. et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults // J. Am. Acad. Dermatol. 2020. Vol. 82. N. 6. P. 1553–1567. DOI: 10.1016/j.jaad.2020.02.066. PMID: 32151629.
  2. Abe J., Mataki K., Umetsu R. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004–2013 // Allergol. Int. 2015. Vol. 64. N. 3. P. 277–279.
  3. Sekula P., Dunant A., Mockenhaupt M. et al. Comprehensive Survival Analysis of a Cohort of Patients with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis // J. Investig. Dermatol. 2013. Vol. 133. P. 1197–1204. [CrossRef] [PubMed].
  4. Micheletti R.G., Chiesa-Fuxench Z., Noe M.H. et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States // J. Invest. Dermatol. 2018. Vol. 138. N. 11. P. 2315–2321.
  5. Cadogan М. Albert Mason Stevens. Life in the Fastlane. 2021. https://litfl.com/albert-mason-stevens/.
  6. Cadogan М. Frank Chambliss Johnson. 2021. https://litfl.com/frank-chambliss-johnson/.
  7. Cadogan М. Alan Lyell. Life in the Fastlane. 2020. https://litfl.com/alan-lyell/.
  8. Maity S., Banerjee I., Sinha R. et al. Nikolsky’s sign: A pathognomic boon // J. Family Med. Prim. Care. 2020. Vol. 9. N. 2. P. 526–530. DOI: 10.4103/jfmpc.jfmpc_889_19. PMID: 32318376. PMCID: PMC7114071.
  9. Murari A., Singh K.N. Lund and Browder chart-modified versus original: a comparative study // Acute Crit. Care. 2019. Vol. 34. N. 4. P. 276–281. DOI: 10.4266/acc.2019.00647. PMID: 31795625. PMCID: PMC6895471.
  10. Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Vol. 390. Issue 10106. P. 1996–2011. DOI: 10.1016/S0140-6736(16)30378-6. PMID: 28476287.
  11. Pichler W.J. Modes of presentation of chemical neoantigens to the immune system // Toxicology. 2002. Vol. 181–182. P. 49–54. DOI: 10.1016/s0300-483x(02)00254-8. PMID: 12505284.
  12. Pichler W.J., Adam J., Watkins S. et al. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors // Int. Arch. Allergy Immunol. 2015. Vol. 168. N. 1. P. 13–24. DOI: 10.1159/000441280. PMID: 26524432.
  13. Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Dermatol. 2015. Vol. 42. N. 1. P. 42–48.
  14. Pichler W.J. Immune pathomechanism and classification of drug hypersensitivity // Allergy. 2019. Vol. 74. N. 8. P. 1457–1471. DOI: 10.1111/all.13765)
  15. Pichler W.J. The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors // World Allergy Organ J. 2008. Vol. 1. N. 6. P. 96–102. DOI: 10.1097/WOX.0b013e3181778282. PMID: 23282405. PMCID: PMC3651037.
  16. Schnyder B., Brockow K. Pathogenesis of drug allergy — current concepts and recent insights // Clin. Exp. Allergy. 2015. Vol. 45. N. 9. P. 1376–1383. DOI: 10.1111/cea.12591. PMID: 26172398.
  17. Yun J., Marcaida M.J., Eriksson K.K. et al. Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58: 01 // J. Immunol. 2014. Vol. 192. N. 7. P. 2984–2993.
  18. Pichler W.J., Beeler A., Keller M. et al. Pharmacological Interaction of Drugs with Immune Receptors: The p-i Concept // Allergol. Int. 2006. Vol. 55. N. 1. P. 17–25.
  19. Yang C.W.O., Hung S.I., Juo C.G. et al. HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2007. Vol. 120. N. 4. P. 870–877.
  20. Lerch M., Mainetti C., Terziroli Beretta-Piccoli B. et al. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis // Clin. Rev. Allergy Immunol. 2018. Vol. 54. N. 1. P. 147–176.
  21. Illing P.T., Vivian J.P., Dudek N.L. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire // Nature. 2012. Vol. 486. Issue 7404. P. 554–558.
  22. Ostrov D.A., Grant B.J., Pompeu Y.A. et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109. N. 25. P. 9959–9964.
  23. Hung S.I., Chung W.H., Liou L.B. et al. HLA–B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. P. 4134–4139.
  24. Wei C.Y., Chung W.H., Huang H.W. et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2012. Vol. 129. N. 6. P. 1562–1569.e5.
  25. Chung W.H., Pan R.Y., Chu M.T. et al. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions // J. Invest. Dermatol. 2015. Vol. 135. N. 9. P. 2237–2248.
  26. Pan R.Y., Chu M.T., Wang C.W. et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions // Nat. Commun. 2019. Vol. 10. N. 1. P. 3569.
  27. Hasegawa A., Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis // F1000Res. 2020. Vol. 9. P. F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1. PMID: 32595945. PMCID: PMC7308994.
  28. Chang W.C., Abe R., Anderson P. et al. SJS/TEN 2019: From science to translation // J. Dermatol. Sci. 2020. Vol. 98. N. 1. P. 2–12. DOI: 10.1016/j.jdermsci.2020.02.003. PMID: 32192826. PMCID: PMC7261636.
  29. Azukizawa H. Animal models of toxic epidermal necrolysis // J. Dermatol. 2011. Vol. 38. N. 3. P. 255–260. DOI: 10.1111/j.1346-8138.2010.01173.x. PMID: 21342227.
  30. Borchers A.T., Lee J.L., Naguwa S.M. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis // Autoimmun. Rev. 2008. Vol. 7. N. 8. P. 598–605. DOI: 10.1016/j.autrev.2008.06.004. PMID: 18603022.
  31. Tohyama M., Watanabe H., Murakami S. et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis // Br. J. Dermatol. 2012. Vol. 166. N. 2. P. 322–330.
  32. Correia O., Delgado L., Roujeau J.C. et al. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples // Arch. Dermatol. 2002. Vol. 138. N. 1. P. 29–32.
  33. Elmore S. Apoptosis: A Review of Programmed Cell Death // Toxicol. Pathol. 2007. Vol. 35. N. 4. P. 495–516.
  34. Lotti R., Shu E., Petrachi T. et al. Soluble Fas Ligand Is Essential for Blister Formation in Pemphigus // Front. Immunol. 2018. Vol. 9. P. 370. DOI: 10.3389/fimmu.2018.00370. PMID: 29535737. PMCID: PMC5834757.
  35. Frazzette N., Cruz A.C., Wu X. et al. Super-Resolution Imaging of Fas/CD95 Reorganization Induced by Membrane-Bound Fas Ligand Reveals Nanoscale Clustering Upstream of FADD Recruitment // Cells. 2022. Vol. 11. N. 12. P. 1908. DOI: 10.3390/cells11121908. PMID: 35741037. PMCID: PMC9221696.
  36. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Soluble Fas ligand involvement in the pathomechanisms of these diseases // J. Dermatol. Sci. 2008. Vol. 52. N. 3. P. 151–159.
  37. Stur K., Karlhofer F.M., Stingl G. Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas // J. Invest. Dermatol. 2007. Vol. 127. N. 4. P. 802–807.
  38. Morel E., Escamochero S., Cabañas R. et al. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Allergy Clin. Immunol. 2010. Vol. 125. N. 3. P. 703–710, 710.e1–710.e8. DOI: 10.1016/j.jaci.2009.10.030. PMID: 2013297.
  39. Su S.C., Mockenhaupt M., Wolkenstein P. et al. Interleukin-15 is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis // J. Invest. Dermatol. 2017. Vol. 137. N. 5. P. 1065–1073. DOI: 10.1016/j.jid.2016.11.034.
  40. Lerch M., Mainetti C., Terziroli Beretta-Piccoli B., Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis // Clin. Rev. Allergy Immunol. 2018. Vol. 54. N. 1. P. 147–176. DOI: 10.1007/s12016-017-8654-z. PMID: 29188475.
  41. Tong J., Chan J. Stevens-Johnson Syndrome Due to Influenza Vaccination // Cureus. 2020. Vol. 12. N. 7. P. e9405. DOI: 10.7759/cureus.9405.
  42. Mittmann N., Knowles S.R., Koo M. et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study // Am. J. Clin. Dermatol. 2012. Vol. 13. N. 1. P. 49–54. DOI: 10.2165/11593240-000000000-00000.
  43. Tseng J., Maurer T., Mutizwa M.M. HIV-Associated Toxic Epidermal Necrolysis at San Francisco General Hospital // J. Int. Assoc. Provid. AIDS Care. 2017. Vol. 16. N. 1. P. 37–41. DOI: 10.1177/2325957415614651.
  44. Cattelan A.M., Trevenzoli M., Sasset L. et al. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature // J. Infect. 2001. Vol. 43. N. 4. P. 246–249. DOI: 10.1053/jinf.2001.0902.
  45. Paik S., Sen S., Era N., Saha B., Tripathi S.K. Fatal Nevirapine-Induced Toxic Epidermal Necrolysis in a HIV Infected Patient // J. Clin. Diagn. Res. 2016. Vol. 10. N. 3. P. FD03-FD6. DOI: 10.7860/JCDR/2016/16360.7415).
  46. Hsu D.Y., Brieva J., Silverberg N.B., Silverberg J.I. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults // J. Invest. Dermatol. 2016. Vol. 136. N. 7. P. 1387–1397. DOI: 10.1016/j.jid.2016.03.023.
  47. Coleman E.L., Olamiju B., Leventhal J.S. The life-threatening eruptions of immune checkpoint inhibitor therapy // Clin. Dermatol. 2020. Vol. 38. N. 1. P. 94–104. DOI: 10.1016/j.clindermatol.2019.10.015. PMID: 32197753.
  48. Zhang L., Shen L., Lu Y., Xue J. Cancer immunotherapy and toxic epidermal necrolysis // BMJ Support Palliat Care. 2020. Vol. 10. N. 3. P. 314–315. DOI: 10.1136/bmjspcare-2019-002135.
  49. Maloney N.J., Ravi V., Cheng K., Bach D.Q., Worswick S. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review // Int. J. Dermatol. 2020. Vol. 59. N. 6. P. e183–e188. DOI: 10.1111/ijd.14811.
  50. Pierard-Franchimont C., Lesuisse M., Humbert P., Delvenne P., Pierard G.E. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy // Curr. Drug Saf. 2012. Vol. 7. N. 5. P. 357–360. DOI: 10.2174/157488612805076543.
  51. Narang I., Panthagani A.P., Lewis M. et al. COVID-19-induced toxic epidermal necrolysis // Clin. Exp. Dermatol. 2021. Vol. 46. N. 5. P. 927–929. DOI: 10.1111/ced.14574.
  52. Shahidi-Dadras M., Araghi F., Ahmadzadeh A. et al. TEN/SJS-like lupus erythematosus presentation complicated by COVID-19 // Dermatol. Ther. 2021. Vol. 34. N. 1. P. e14612. DOI: 10.1111/dth.14612.
  53. Tanaka A., Isei M., Kikuzawa C. et al. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA // J. Dermatol. 2021. Vol. 48. N. 3. P. e144–e145. DOI: 10.1111/1346-8138.15753.
  54. Saha M., D’Cruz A., Paul N. et al. Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: ‘Killing 2 birds with one stone’ // J. Eur. Acad. Dermatol. Venereol. 2021. Vol. 35. N. 2. P. e97–e98. DOI: 10.1111/jdv.16887).
  55. Aulakh S., Arora R., Sarangal R., Chopra D. Increased Predisposition of SJS TEN in COVID-19 Patients, Presenting as Post COVID Complication: Report of Two Cases // Indian Dermatol. Online J. 2022. Vol. 13. N. 2. P. 237–239. DOI: 10.4103/idoj.idoj_510_2.
  56. Rossi C.M., Beretta F.N., Traverso G.et al. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime // Clin. Mol. Allergy. 2020. N. 18. P. 19. DOI: 10.1186/s12948-020-00133-6.
  57. Fan W.Y., Zhai Q.R., Ma Q.B., Ge H.X. Toxic epidermal necrolysis with systemic lupus erythematosus: case report and review of the literature // Ann. Palliat. Med. 2021. N. apm-21-341. DOI: 10.21037/apm-21-341. PMID: 34412491.
  58. Ng C.Y., Chen C.B., Wu M.Y. et al. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies // J. Immunol. Res. 2018. Vol. 5376476. DOI: 10.1155/2018/5376476. PMID: 29577050. PMCID: PMC5822766.
  59. Gatson N.T., Travers J.B., Al-Hassani M. et al. Progression of toxic epidermal necrolysis after tanning bed exposure // Arch. Dermatol. 2011. Vol. 147. N. 6. P. 719–723. DOI: 10.1001/archdermatol.2011.13.
  60. Velázquez-Cárcamo E.A., Rodríguez-Chávez Y., Méndez-Flores S., Domínguez-Cherit J. Lamotrigina y su relación con el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica [Lamotrigine and its relationship with Stevens-Johnson syndrome and toxic epidermal necrolysis] // Rev. Med. Inst. Mex. Seguro Soc. 2020. Vol. 58. N. 2. P. 202–205. Spanish. DOI: 10.24875/RMIMSS.M20000018. PMID: 34101565.
  61. Mansur A.T., Aydingöz I.A. A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin // Photodermatol. Photoimmunol. Photomed. 2005. Vol. 21. N. 2. P. 100–102. DOI: 10.1111/j.1600-0781.2005.00149.x
  62. Kridin K., Brüggen M.C., Chua S.L. et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study // JAMA Dermatol. 2021. Vol. 157. N. 10. P. 1182–1190. DOI: 10.1001/jamadermatol.2021.3154. PMID: 34431984. PMCID: PMC8387938.
  63. Shanbhag S.S., Sangwan V.S., Singh A. et al. Clinical Aspects of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications in India // Front. Med. (Lausanne). 2021. N. 8. P. 643955. DOI: 10.3389/fmed.2021.643955. PMID: 34513854. PMCID: PMC8429498.
  64. Chen C.B., Abe R., Pan R.Y. et al. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity // J. Immunol. Res. 2018 F. Vol. 2018. P. 6431694. DOI: 10.1155/2018/6431694. PMID: 29651444. PMCID: PMC5830968.
  65. Ueta M. Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications // Front. Med. (Lausanne). 2021. N. 8. P. 651247. DOI: 10.3389/fmed.2021.651247. PMID: 34869401. PMCID: PMC8635481.
  66. Capule F., Tragulpiankit P., Mahasirimongkol S. et al. HLA-A*24:07 as a potential biomarker for carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Filipino patients // Pharmacogenomics. 2021. Vol. 22. N. 8. P. 465–472. DOI: 10.2217/pgs-2020-0191. Epub 2021 Apr 29. PMID: 33910375. PMCID: PMC8191649.
  67. Hasegawa A., Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis // F1000Res. 2020. Vol. 9. P. F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1.
  68. Li X., Yu K., Mei S. et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies // Drug Res. (Stuttg). 2015. Vol. 65. N. 2. P. 107–111. DOI: 10.1055/s-0034-1375684.
  69. Tangamornsuksan W., Chaiyakunapruk N., Somkrua R. et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis // JAMA Dermatol. 2013. Vol. 149. N. 9. P. 1025–1032. DOI: 10.1001/jamadermatol.2013.4114.
  70. Wang Q., Sun S., Xie M. et al. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis // Epilepsy Res. 2017. Vol. 135. P. 19–28. DOI: 10.1016/j.eplepsyres.2017.05.015).
  71. Nicoletti P., Barrett S., McEvoy L. et al. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions // Clin. Pharmacol. Ther. 2019. Vol. 106. N. 5. P. 1028–1036. DOI: 10.1002/cpt.1493. PMID: 31066027. PMCID: PMC7156285.
  72. Shi Y.W., Min F.L., Zhou D. et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions // Neurology. 2017. Vol. 88. N. 23. P. 2183–2191. DOI: 10.1212/WNL.0000000000004008.
  73. Yu K.H., Yu C.Y., Fang Y.F. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis // Int. J. Rheum. Dis. 2017. Vol. 20. N. 9. P. 1057–1071. DOI: 10.1111/1756-185X.13143. PMID: 28857441.
  74. Small C.B., Margolis D.A., Shaefer M.S., Ross L.L. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects // BMC Infect. Dis. 2017. Vol. 17. N. 1. P. 256. DOI: 10.1186/s12879-017-2331-y. PMID: 28399804. PMCID: PMC5387336.
  75. Tempark T., Satapornpong P., Rerknimitr P. et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population // Pharmacogenet. Genomics. 2017. Vol. 27. N. 12. P. 429–437. DOI: 10.1097/FPC.0000000000000306.
  76. Ko T.M., Chung W.H., Wei C.Y. et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome // J. Allergy Clin. Immunol. 2011. Vol. 128. N. 6. P. 1266–1276.e11. DOI: 10.1016/j.jaci.2011.08.013.
  77. Manuyakorn W., Siripool K., Kamchaisatian W. et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children // Pediatr. Allergy Immunol. 2013. Vol. 24. N. 3. P. 299–303. DOI: 10.1111/pai.12058).
  78. Bastuji-Garin S., Rzany B., Stern R.S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme // Arch. Dermatol. 1993. Vol. 129. P. 92e6.
  79. Creamer D., Walsh S.A., Dziewulski P. et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 // Br. J. Dermatol. 2016. Vol. 174. N. 6. P. 1194–1227. DOI: 10.1111/bjd.14530. PMID: 27317286.
  80. Auquier-Dunant A., Mockenhaupt M., Naldi L. et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study // Arch. Dermatol. 2002. Vol. 138. P. 1019–1024.
  81. Copaescu A.M., Trublano J.A. The assessment of severe cutaneous adverse drug reactions // Aust Prescr. 2022. Vol. 45. N. 2. P. 43–48. DOI: 10.18773/austprescr.2022.010. Epub 2022 Apr 1. PMID: 35592375. PMCID: PMC908193.
  82. Harman K.E., Brown D., Exton L.S. et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris // Br. J. Dermatol. 2017. Vol. 177. P. 1170–1201.
  83. Melchionda V., Harman K.E. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management // Clin. Exp. Dermatol. 2019. Vol. 44. N. 7. P. 740–746. DOI: 10.1111/ced.14041. PMID: 31378971.
  84. Broussard K.C., Leung T.G., Moradi A., Thorne J.E., Fine J.D. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica // Clin. Dermatol. 2016. Vol. 34. N. 2. P. 205–213. DOI: 10.1016/j.clindermatol.2015.11.006.
  85. Parker S.R., MacKelfresh J. Autoimmune blistering diseases in the elderly // Clin. Dermatol. 2011. Vol. 29. N. 1. P. 69–79. DOI: 10.1016/j.clindermatol.2010.07. 010.
  86. Jascholt I., Lai O., Zillikens D., Kasperkiewicz M. Periodontitis in oral pemphigus and pemphigoid: a systematic review of published studies // J. Am. Acad. Dermatol. 2017. Vol. 76. N. 5. P. 975–978. DOI: 10.1016/j.jaad.2016.10.028.
  87. Barea-Jiménez N., Calero J., Molina-Negrón D., López Del-Valle L.M. Treatment for oral lesions in pediatric patients with Stevens-Johnson’s syndrome: A case report and literature review // Int. J. Paediatr Dent. 2020. Vol. 30. N. 4. P. 489–496. DOI: 10.1111/ipd.12615. PMID: 31923328.
  88. Ramos-e-Silva M., Ferreira A., Jacques C. Oral involvement in autoimmune bullous diseases // Clin. Dermatol. 2011. Vol. 29. N. 4. P. 443–454. DOI: 10.1016/j. clindermatol.2011.01.015.
  89. Kasperkiewicz M., Ellebrecht C.T., Takahashi H. et al. Pemphigus // Nat. Rev. Dis. Primers 2017. Vol. 3. P. 17026. DOI: 10.1038/ nrdp.2017.26.
  90. Amber K.T., Valdebran M., Grando S.A. Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus // Autoimmun. Rev. 2018. Vol. 17. N. 10. P. 1002–1010. DOI: 10.1016/j.autrev.2018. 04.008.
  91. Miyamoto D., Santi C.G., Aoki V., Maruta C.W. Bullous pemphigoid // An. Bras. Dermatol. 2019. Vol. 94. N. 2. P. 133–146. DOI: 10.1590/abd1806-4841.20199007. PMID: 31090818. PMCID: PMC6486083.
  92. Di Zenzo G., Marazza G., Borradori L. Bullous pemphigoid: physiopathology, clinical features and management // Adv. Dermatol. 2007. Vol. 23. P. 257–288.
  93. Lamb P.M., Abell E., Tharp M., Frye R., Deng J.S. Prodromal bullous pemphigoid // Int. J. Dermatol. 2006. Vol. 45. P. 209–214.
  94. Bağcı I.S., Horváth O.N., Ruzicka T., Sárdy M. Bullous pemphigoid // Autoimmun. Rev. 2017. Vol. 16. N. 5. P. 445–455. DOI: 10.1016/j.autrev.2017.03.010. PMID: 28286109.
  95. Tirado-Sánchez A., Bonifaz A. Paraneoplastic Pemphigus. A Life-Threatening Autoimmune Blistering Disease // Actas Dermosifiliogr. 2017. Vol. 108. N. 10. P. 902–910. English, Spanish. DOI: 10.1016/j.ad.2017.04.024. PMID: 28801011.
  96. Duan L., Chen L., Zhong S. et al. Treatment of Bullous Systemic Lupus Erythematosus // J. Immunol. Res. 2015. Vol. 2015. P. 167064. DOI: 10.1155/2015/167064. PMID: 26090480. PMCID: PMC4451988.
  97. Rutnin S., Chanprapaph K. Vesiculobullous diseases in relation to lupus erythematosus // Clin. Cosmet. Investig. Dermatol. 2019. Vol. 12. P. 653–667. DOI: 10.2147/CCID.S220906. PMID: 31564947. PMCID: PMC6732903.
  98. Lammer J., Hein R., Roenneberg S. et al. Drug-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature // Acta Derm. Venereol. 2019. Vol. 99. N. 6. P. 508–515. DOI: 10.2340/00015555-3154. PMID: 30809685.
  99. Patel S., John A.M., Handler M.Z., Schwartz R.A. Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption // Am. J. Clin. Dermatol. 2020. Vol. 21. N. 3. P. 393–399. DOI: 10.1007/s40257-020-00505-3. PMID: 32002848.
  100. Abate M.S., Battle L.R., Emerson A.N. et al. Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know // Arch. Pathol. Lab. Med. 2019. Vol. 143. N. 8. P. 919–942. DOI: 10.5858/arpa.2018-0239-RA. PMID: 30785787.
  101. Zeiser R., Blazar B.R. Acute Graft-versus-Host Disease Biology, Prevention and Therapy // N. Engl. J. Med. 2017. Vol. 377. N. 22. P. 2167–2179. DOI: 10.1056/NEJMra1609337.
  102. Szatkowski J., Schwartz R.A. Acute generalized exanthematous pustulosis (AGEP): A review and update // J. Am. Acad. Dermatol. 2015. Vol. 73. N. 5. P. 843–848. DOI: 10.1016/j.jaad.2015.07.017. PMID: 26354880.
  103. Gonçalves R., Gata L., Brett A. Mycoplasma pneumoniae-associated mucositis // BMJ Case Rep. 2021. Vol. 14. N. 4. P. e239086. DOI: 10.1136/bcr-2020-239086. PMID: 33858884. PMCID: PMC8054042.
  104. Abela C., Hartmann C.E., De Leo A. et al. Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm // J. Plast. Reconstr. Aesthet. Surg. 2014. Vol. 67. N. 8. P. 1026–1032. DOI: 10.1016/j.bjps.2014.04.003. PMID: 24860933.
  105. Heng J.S., Malik N., Joshi N. et al. Severity of acute ocular involvement is independently associated with time to resolution of ocular disease in toxic epidermal necrolysis patients // Br. J. Opthalmol. 2015. Vol. 99. N. 2. P. 251–254.
  106. Gueudry J., Roujeau J.C., Binaghi M. et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis // Arch. Dermatol. 2009. Vol. 145. N. 2. P. 157–162.
  107. Lopez-Garcia J.S., Rivas Jara L., Garcia-Lozano C.I. et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis // Ophthalmology. 2011. Vol. 118. N. 2. P. 265–271.
  108. Meneux E., Wolkenstein P., Haddad B. et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases // Obstet. Gynecol.1998. Vol. 91. N. 2. P. 283–287.
  109. Van Batavia J.P., Chu D.I., Long C.J. et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Pediatr. Urol. 2017. Vol. 13. N. 5. P. 490.e1–490.e7.
  110. Boyraz G., Basaran D., Salman M.C. et al. Vaginal reconstruction for vaginal obliteration secondary to Stevens Johnson syndrome: a case report and review of literature // Oman Med. J. 2017. Vol. 32. N. 5. P. 436–439.
  111. Kaser D.J., Reichman D.E., Laufer M.R. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis // Rev. Obstetr. Gynecol. 2011. Vol. 4. N. 2. P. 81–85.
  112. Lee H.Y., Walsh S.A., Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up // Br. J. Dermatol. 2017. Vol. 177. N. 4. P. 924–935.
  113. Saeed H., Mantagos I.S., Chodosh J. Complications of Stevens-Johnson syndrome beyond the eye and skin // Burns. 2016. Vol. 42. N. 1. P. 20–27.
  114. Reddy R.B., Shekar P.C., Chandra K.L., Aravind R. Oral lesions associated with nevirapine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of 10 cases // J. Oral. Maxillofac. Pathol. 2013. Vol. 17. N. 3. P. 431–435.
  115. Sedghizadeh P.P., Kumar S.K., Gorur A., Mastin C., Boros A.L. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention // Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2008. Vol. 105. N. 4. P. e29–e33.
  116. Weinkle A., Pettit C., Jani A. et al. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation — a retrospective chart review // J. Am. Acad. Dermatol. 2019. Vol. 81. N. 3. P. 749–757.
  117. de Prost N., Ingen-Housz-Oro S., Duong T. et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures // Medicine. 2010. Vol. 89. N. 1. P. 28–36.
  118. Kim H.I., Kim S.W., Park G.Y. et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients // Korean J. Intern. Med. 2012. Vol. 27. N. 2. P. 203–210.
  119. Shanbhag S.S., Chodosh J., Fathy C. et al. Multidisciplinary care in Stevens-Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11: 2040622319894469. DOI: 10.1177/2040622319894469. PMID: 32523661. PMCID: PMC7236394.
  120. Ducic I., Shalom A., Rising W. et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited // Plast. Reconstr. Surg. 2002. Vol. 110. P. 768–773.
  121. Noe M.H., Rosenbach M., Hubbard R.A. et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10 // JAMA Dermatol. 2019. Vol. 155. N. 4. P. 448–454. DOI: 10.1001/jamadermatol.2018.5605. PMID: 30840032. PMCID: PMC6459085.
  122. Bastuji-Garin S., Fouchard N., Bertocchi M. et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis // J. Invest. Dermatol. 2000. Vol. 115. N. 2. P. 149–153. DOI: 10.1046/j.1523-1747.2000.00061.x. PMID: 10951229.
  123. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: A severity of disease classification system // Crit. Care Med. 1985. Vol. 13. P. 818–829.
  124. Marshall J.C., Cook D.J., Christou N.V. et al. Multiple Organ Dysfunction Score: a reliable descriptor of a complex clinical outcome // Crit. Care Med. 1995. Vol. 23. P. 1638–1652.
  125. Schulz J.T., Sheridan R.L., Ryan C.M. et al. A 10-year experience with toxic epidermal necrolysis // J. Burn. Care Rehabil. 2000. Vol. 21. P. 199e204.
  126. McGee T., Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center // Plast. Reconstr. Surg. 1998. Vol. 102. P. 1018e22.
  127. Valeyrie-Allanore L., Ingen-Housz-Oro S., Chosidow O., Wolkenstein P. French referral center management of Stevense Johnson syndrome/toxic epidermal necrolysis // Dermatol. Sin. 2013. Vol. 31. N. 4. P. 191–195.
  128. Herndon D.N. Mediators of metabolism // J. Trauma 1981. Vol. 21. P. 701e5.
  129. Herndon D.N., Tompkins R.G. Support of the metabolic response to burn injury // Lancet 2004. Vol. 363. Issue 1895. P. e902.
  130. Arnold M., Yanez C., Yanez B. Wound Healing in the Long-Term Acute Care Setting Using an Air Fluidized Therapy/Continuous Low-Pressure Therapeutic Bed: A Multiple Case Series // J. Wound Ostomy Continence Nurs. 2020. Vol. 47. N. 3. P. 284–290. DOI: 10.1097/WON.0000000000000646. PMID: 32384532.
  131. Winters W.D. A new perspective of microbial survival and dissemination in a prospectively contaminated air-fluidized bed model // Am. J. Infect. Control. 1990. Vol. 18. N. 5. P. 307–315. DOI: 10.1016/0196-6553(90)90230-p. PMID: 2123611.
  132. Papp A., Sikora S., Evans M. et al. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results // Burns. 2018. Vol. 44. N. 4. P. 807–815. DOI: 10.1016/j.burns.2017.10.022. PMID: 29627131.
  133. Paquet P., Piérard G.E. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN) // Exp. Opin.Pharmacother. 2010. Vol. 11. N. 15. P. 2447–2458. DOI: 10.1517/14656566.2010.51558.
  134. Duong T.A., Valeyrie-Allanore L., Wolkenstein P., Chosidow O. Severe cutaneous adverse reactions to drugs // Lancet. 2017. Vol. 390. Issue 10106. P. 1996–2011. DOI: 10.1016/S0140-6736(16)30378-6. PMID: 28476287.
  135. Whiteley I., Sinclair G., Lyons A.M., Riccardi R. A retrospective review of outcomes using a fecal management system in acute care patients // Ostomy Wound Manage. 2014. Vol. 60. N. 12. P. 37–43. PMID: 25485551.
  136. Charlton O.A., Harris V., Phan K. et al.Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review // Adv. Wound Care (New Rochelle). 2020. Vol. 9. N. 7. P. 426–439. DOI: 10.1089/wound.2019.0977. PMID: 32520664. PMCID: PMC7307670.
  137. Noe M.H., Micheletti R.G. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis // Clin. Dermatol. 2020. Vol. 38. N. 6. P. 607–612. DOI: 10.1016/j.clindermatol.2020.06.016. PMID: 33341195.
  138. Choi H., Castillo B., Seminario-Vidal L. Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series // Int. Wound J. 2018. Vol. 15. N. 6. P. 1049–1051. DOI: 10.1111/iwj.12938. PMID: 29893032. PMCID: PMC7949585.
  139. Lindford A.J., Kaartinen I.S., Virolainen S., Vuola J. Comparison of Suprathel® and allograft skin in the treatment of a severe case of toxic epidermal necrolysis // Burns. 2011. Vol. 37. N. 7. P. e67–72. DOI: 10.1016/j.burns.2011.07.015. PMID: 21852045.
  140. Lindford A., Vuola J. Re: Toxic epidermal necrolysis (TEN): The Chelsea and Westminster hospital wound management algorithm // J. Plast. Reconstr. Aesthet. Surg. 2015. Vol. 68. N. 2. P. 288–289. DOI: 10.1016/j.bjps.2014.09.031. PMID: 25282634.
  141. Pfurtscheller K., Zobel G., Roedl S., Trop M. Use of Suprathel dressing in a young infant with TEN // Pediatr. Dermatol. 2008. Vol. 25. N. 5. P. 541–543. DOI: 10.1111/j.1525–1470.2008.00766.x. PMID: 18950395.
  142. Solanki N.S., Nowak K.M., Mackie I.P., Greenwood J.E. Using biobrane: techniques to make life easier // Eplasty. 2010. Vol. 10. P. e70. PMID: 21187941. PMCID: PMC3008156.
  143. Dillon C.K., Lloyd M.S., Dzeiwulski P. Accurate debridement of toxic epidermal necrolysis using Versajet // Burns. 2010. Vol. 36. N. 4. P. 581–584. DOI: 10.1016/j.burns.2008.12.011. PMID: 19423228.
  144. Mahar P.D., Wasiak J., Hii B. et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres // Burns 2014. Vol. 40. P. 1245e54.
  145. Lee H.Y. Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need // J. Am. Acad. Dermatol. 2018. Vol. 79. N. 4. P. e87–e88. DOI: 10.1016/j.jaad.2018.05.1258. PMID: 29913262.
  146. Koh H.K., Chai Z.T., Tay H.W. et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients // J. Am. Acad. Dermatol. 2019. Vol. 81. N. 3. P. 686–693.
  147. Cartotto R. Burn center care of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // Clin. Plast. Surg. 2017. Vol. 44. N. 3. P. 583–595.
  148. Bequignon E., Duong T.A., Sbidian E. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission // JAMA Dermatol. 2015. Vol. 151. N. 3. P. 302–307.
  149. Oh S.J., Kwon H.I., Moon S.H. et al. Toxic epidermal necrolysis with isolated neutropenia related to the use of levetiracetam // J. Dermatol. 2016. Vol. 43. N. 8. P. 969–971.
  150. Mahajan R., Kanwar A.J. Use of granulocyte colony-stimulating factor in the treatment of toxic epidermal necrolysise experience with 3 patients // Skinmed. 2013. Vol. 11. N. 5. P. 269–271.
  151. Valeyrie-Allanore L., Ingen-Housz-Oro S., Colin A. et al. Pain management in Stevens-Johnson syndrome, toxic epidermal necrolysis and other blistering diseases // Ann. Dermatol. Venereol. 2011. Vol. 138: 694–697. P. quiz 2–3, 8.
  152. Jennes S., Pierard G.E., Paquet P. Deciphering supportive treatment strategies for toxic epidermal necrolysis // Curr. Drug. Saf. 2012. Vol. 7. P. 361–366.
  153. Kohanim S., Palioura S, Saeed H.N. et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis-a comprehensive review and guide to therapy. II. Ophthalmic disease // Ocul. Surf. 2016. Vol. 14. N. 2. P. 168–188.
  154. Sotozono C., Ueta M, Koizumi N. et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications // Ophthalmology. 2009. Vol. 116. N. 4. P. 685–690.
  155. Saeed H.N., Chodosh J. Ocular manifestations of Stevens-Johnson syndrome and their management // Curr. Opin. Ophthalmol. 2016. Vol. 27. N. 6. P. 522–529.
  156. Ciralsky J.B., Sippel K.C., Gregory D.G. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis // Curr. Opin. Ophthalmol. 2013. Vol. 24. N. 4. P. 321–328.
  157. Agrawal A., Pratap V.B. Amniotic membrane transplantation (AMT) without the use of sutures/fibrin glue // Nepal J. Ophthalmol. 2015. Vol. 7. N. 14. P. 173–177.
  158. Kim M.K., Yoon K.C., Yoon S.H., Seo K.Y. Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea // Front. Med. (Lausanne). 2021. Vol. 8. P. 640360. DOI: 10.3389/fmed.2021.640360. PMID: 33693020. PMCID: PMC7937613.
  159. Ma K.N., Thanos A., Chodosh J., Shah A.S., Mantagos I.S. A novel technique for amniotic membrane transplantation in patients with acute Stevens-Johnson syndrome // Ocul. Surf. 2016. Vol. 14. N. 1. P. 31–36.
  160. Sedghizadeh P.P., Kumar S.K., Gorur A. et al. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention // Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2008. Vol. 105. P. e29e33.
  161. Roujeau J.C., Phlippoteau C., Koso M. et al. Sjo¨gren-like syndrome after drug-induced toxic epidermal necrolysis // Lancet 1985. Vol. 1: 609e11.
  162. Shazib M.A., Muhlbauer J., Schweiker R., Li S., Cutler C., Treister N. Long-term utilization patterns of topical therapy and clinical outcomes of oral chronic graft-versus-host disease // Biol. Blood Marrow Transplant. 2020. Vol. 26. N. 2. P. 373–379.
  163. Rugo H.S., Seneviratne L., Beck J.T. et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial // Lancet Oncol. 2017. Vol. 18. N. 5. P. 654–662.
  164. Sibaud V., Eid C., Belum V.R. et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings // J. Eur. Acad. Dermatol. Venereol. 2017. Vol. 31. N. 10. P. e464–e469.
  165. Campbell L., Emmerson E., Davies F. et al. Estrogen promotes cutaneous wound healing via estrogen receptor beta independent of its antiinflammatory activities // J. Exp. Med. 2010. Vol. 207. N. 9. P. 1825–1833.
  166. Van Batavia J.P., Chu D.I., Long C.J., Jen M., Canning D.A., Weiss D.A. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Pediatr. Urol. 2017. Vol. 13. N. 5. P. 490.e1–490.e7.
  167. Buchan A., Merideth M.A., Childs R.W., Stratton P. Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos // BMJ Case Rep. 2018.
  168. Ching J.A., Kuykendall L.V., Troy J.S., Smith D.J. Jr. Estrogen treatment of acetic acid burns to the vagina, cervix, and perineum: a case report and review of the literature // J. Burn. Care Res. 2014. Vol. 35. N. 5. P. e368–e371.
  169. Shanbhag S.S., Chodosh J., Fathy C. et al. Multidiscipli-nary care in Stevens-Johnson syndrome // Ther. Adv. Chronic Dis. 2020. Vol. 11. P. 2040622319894469. DOI: 10.1177/2040622319894469. PMID: 32523661. PMCID: PMC7236394.
  170. Shiga S., Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? // J. Burn. Care Res. 2010. Vol. 31. N. 1. P. 100–104.
  171. Namdar T., von Wild T., Siemers F. et al. Does hypernatremia impact mortality in toxic epidermal necrolysis? // Ger. Med. Sci. 2010. Vol. 8. P. Doc30.
  172. Schwartz R.A., McDonough P.H., Lee B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment // J. Am. Acad. Dermatol. 2013. Vol. 69. N. 2. P. 187.e1–187.e16. quiz 203–204.
  173. Schneider J.A., Cohen P.R. Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis // J. Am. Acad. Dermatol. 2017. Vol. 77. N. 4. P. e117.
  174. Gupta L.K., Martin A.M., Agarwal N. et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective // Indian J. Dermatol. Venereo.l Leprol. 2016. Vol. 82. N. 6. P. 603–625.
  175. Jennes S., Pierard G.E., Paquet P. Deciphering supportive treatment strategies for toxic epidermal necrolysis // Curr. Drug Saf. 2012. Vol. 7. N. 5. P. 361–366. DOI: 10.2174/157488612805076570. PMID: 23373547.
  176. Stoecklin P., Delodder F., Pantet O., Berger M.M. Moderate glycemic control safe in critically ill adult burn patients: a 15 year cohort study // Burns. 2016. Vol. 42. N. 1. P. 63–70.
  177. Beck A., Cooney R, Gamelli R.L., Mosier M.J. Predicting mechanical ventilation and mortality: early and late indicators in Steven-Johnson syndrome and toxic epidermal necrolysis // J. Burn. Care Res. 2016. Vol. 37. N. 1. P. e47–e55.
  178. de Prost N., Mekontso-Dessap A., Valeyrie-Allanore L. et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation // Crit. Care Med. 2014. Vol. 42. N. 1. P. 118–128.
  179. Williams R., Hodge J., Ingram W. Indications for intubation and early tracheostomy in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis // Am. J. Surg. 2016. Vol. 211. N. 4. P. 684–688.e1.
  180. Brower R.G., Matthay M.A., Morris A. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome // N. Engl. J. Med. 2000. Vol. 342. N. 18. P. 1301–1308.
  181. Halebian P.H., Corder V.J., Madden M.R., Finklestein J.L., Shires G.T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids // Ann. Surg. 1986. Vol. 204. P. 503–512.
  182. Michaels B., del Rosso J.Q. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome a review of past and current opinions // J. Clin. Aesthetic Dermatol. 2009. Vol. 2. P. 51.
  183. Workswick S., Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options // Dermatol. Ther. 2011. Vol. 24. P. 207–218.
  184. Zimmermann S., Sekula P., Venhoff M. et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis // JAMA Dermatol. 2017. Vol. 153. P. 514–522. [CrossRef] [PubMed].
  185. Kardaun S.H., Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis // Acta Derm. Venereol. 2007. Vol. 87. P. 144–148.
  186. McPherson T., Exton L.S., Biswas S. et al. British Association of Dermatologists’ guide-lines for the management of Stevens–Johnson syndrome/Toxic Epidermal Necrolysis in children and young people // Br. J. Dermatol. 2019. Vol. 181. P. 37–54. [CrossRef] [PubMed].
  187. Lee H.Y., Lim Y.L., Thirumoorthy T. et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre // Br. J. Dermatol. 2013. Vol. 169. P. 1304–1309.
  188. Yang L., Shou Y.H., Li F. et al. Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China // Front. Pharmacol. 2022. Vol. 12. P. 750173. DOI: 10.3389/fphar.2021.750173. PMID: 35115922. PMCID: PMC8804212.
  189. Schneck J., Fagot J.P., Sekula P. et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study // J. Am. Acad. Dermatol. 2008. Vol. 58. P. 33–40.
  190. Murphy J.T., Purdue G.F., Hunt J.L. Toxic epidermal necrolysis // J. Burn. Care Rehabil. 1997. Vol. 18. P. 417–420.
  191. Tsai T.Y., Huang I.H., Chao Y.C. et al. Treating Toxic Epidermal Necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis // J. Am. Acad. Dermatol. 2021. Vol. 84. P. 390–397. [CrossRef].
  192. Fernandez A.P., Kerdel F.A. The use of i.v. IG therapy in dermatology // Dermatol. Ther. 2007. Vol. 20. P. 288–305. [CrossRef] [PubMed].
  193. Zhu Q.Y., Ma L., Luo X.Q., Huang H.Y. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China // J. Burn. Care Res. 2012. Vol. 33. P. e295–308.
  194. Narita Y.M., Hirahara K., Mizukawa Y. et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? // J. Dermatol. 2011. Vol. 38. P. 236–245.
  195. Kuprash D.V., Boitchenko V.E., Yarovinsky F.O. et al. Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells // Blood 2002. Vol. 100. P. 1721–1727.
  196. Valeyrie-Allanore L., Wolkenstein P., Brochard L. et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis // Br. J. Dermatol. 2010. Vol. 163. P. 847–853.
  197. Arevalo J.M., Lorente J.A., Gonzalez-Herrada C., Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporine A // J. Trauma 2000. Vol. 48. P. 473–478.
  198. Singh G.K., Chatterjee M., Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid // Indian J. Dermatol. Venereol. Leprol.2013. Vol. 79. P. 686–692.
  199. Kirchhof M.G., Miliszewski M.A., Sikora S. et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine // J. Am. Acad. Dermatol. 2014. Vol. 71. P. 941–947.
  200. Zaki I., Patel S., Reed R. et al. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporine // Br. J. Dermatol 1995. Vol. 133. P. 337–338.
  201. Zhang S., Tang S. et al. Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis: A systemic review // J. Dermatol. Treat. 2020. Vol. 31. P. 66–73. [CrossRef] [PubMed].
  202. Wang C.W., Yang L.Y., Chen C.B. et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions // J. Clin. Investig. 2018. Vol. 128. P. 985–996. [CrossRef].
  203. Jarrett P., Rademaker M., Havill J. et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor // Clin. Exp. Dermatol. 1997. Vol. 22. P. 146–147.
  204. Winfred R.I., Nanda S., Horvath G. et al. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor // South Med. J. 1999. Vol. 92. P. 918–920.
  205. Robak E., Robak T., Gora-Tybor J. et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF // J. Med. 2001. Vol. 32. P. 31–39.
  206. Han F., Zhang J., Guo Q. et al. Successful treatment of Toxic Epidermal Necrolysis using plasmapheresis: A prospective observational study // J. Crit. Care 2017. Vol. 42. P. 65–68. [CrossRef] [PubMed]
  207. Frantz R., Huang S., Are A., Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management // Medicina (Kaunas). 2021 Aug 28. Vol. 57. N. 9. P. 895. DOI: 10.3390/medicina57090895. PMID: 34577817. PMCID: PMC8472007.
  208. Butt T.F., Cox A.R., Lewis H. et al. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK // Drug Saf 2011. Vol. 34. P. 319e28.
  209. Sotozono C., Ang L.P., Koizumi N. et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome // Ophthalmology 2007. Vol. 114. P. 1294e302.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*